Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
Shukui Qin(81th Hospital of PLA), Jin Li(Hainan Medical University), Jiejun Wang(Shanghai Changzheng Hospital), Ying Yuan(Zhejiang Cancer Hospital), Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongming Pan(Sir Run Run Shaw Hospital), Ying Cheng(Jilin Province Tumor Hospital), Lin Shen(Peking University), Haihui Chen(Liuzhou Maternal and Child Health Hospital), Xiaojun Guo(China Banking Regulatory Commission), Hongbing Wang(University of Maryland, Baltimore), Yuxian Bai(Harbin Medical University), Wei Li(Jilin University), Qiang Zhang(Nanjing University of Chinese Medicine), Ning Wang(Shanghai Ninth People's Hospital), Bin Zhang(Guangzhou University of Chinese Medicine), Donghui Chen(University of Washington), Zhuang Yu(Shanghai East Hospital), Tianshu Liu(Sun Yat-sen University), Shubin Wang(Hong Kong University of Science and Technology), Dong Ma, Haijun Zhong(Zhejiang Cancer Hospital), Jianming Xu(Chinese PLA General Hospital), Zhendong Chen(University of Cologne), Weijian Guo, Rui‐Hua Xu(Sun Yat-sen University), Yongqian Shu(Jiangsu Provincial Hospital of Traditional Chinese Medicine), Lei Yang(Nantong Tumor Hospital), Changping Wu(Soochow University), Sanyuan Sun(Xuzhou Central Hospital), Weiguo Su(Tamedia (Switzerland)), Peiguo Cao(Central South University), Nong Xu(First Affiliated Hospital Zhejiang University), Yanhong Deng(Sun Yat-sen University)
Cited by 7
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k